Forskolin Pre-adipocyte Targeting for Adipogenesis Inhibition

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods fail to effectively achieve optimal mammalian energy balance, as they struggle to inhibit adipogenesis and enhance the expression of secreted factors that recruit brown adipose tissue, leading to metabolic diseases such as obesity.

Innovation Solution

Forskolin is administered to pre-adipocytes rather than mature adipocytes to inhibit adipogenesis and enhance the expression of secreted factors like BMP-7, BMP-4, VEGF-A, and UCP1, promoting the differentiation into brown adipose tissue.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If forskolin is administered to mature adipocytes, then some inhibition of adipogenesis occurs, but the inhibition effect is insufficient to achieve optimal energy balance

Engineering Contradiction:
Improveadipogenesis inhibition efficacyVSAvoidenergy balance achievement
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent applies preliminary action by administering forskolin to pre-adipocytes before they differentiate into mature adipocytes. This timing allows the compound to prevent adipogenesis before it fully occurs, rather than attempting to reverse it in mature cells. The method treats the cellular state at an earlier developmental stage where intervention is more effective for achieving energy balance.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent utilizes parameter changes by exploiting the temporal parameter (developmental stage) of adipocyte differentiation. By changing when forskolin is administered in the differentiation timeline - from mature adipocytes to pre-adipocytes - the efficacy of adipogenesis inhibition is dramatically enhanced, transforming the effectiveness parameter from insufficient to highly effective.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If forskolin is administered to pre-adipocytes, then adipogenesis inhibition is dramatically enhanced, but the complexity of timing and targeting increases

Engineering Contradiction:
Improveadipogenesis inhibition efficacyVSAvoidadministration timing and targeting
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by administering forskolin to pre-adipocytes before they differentiate into mature adipocytes. This timing allows the compound to prevent adipogenesis before it fully occurs, rather than attempting to reverse it in mature cells. The method treats the cellular state at an earlier developmental stage where intervention is more effective for achieving energy balance.

Inventive Principle:
Principle #10Preliminary action

3Reliability

If forskolin is administered to pre-adipocytes, then expression of brown adipose tissue recruiting factors is enhanced, but the specificity of targeting pre-adipocytes versus mature adipocytes must be maintained

Engineering Contradiction:
Improvebrown adipose tissue recruitmentVSAvoidcell type targeting specificity
Core Design Contradiction:
ReliabilityVSManufacturing precision

Solution Approach 1:

The patent applies local quality by creating different functional responses in different cellular states. Pre-adipocytes and mature adipocytes exhibit different responses to forskolin administration. By targeting pre-adipocytes specifically, the method activates brown adipose tissue recruiting factor expression (BMP-7, BMP-4, VEGF-A, UCP1) with high effectiveness, while avoiding the diminished response seen in mature adipocytes.

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Forskolin significantly inhibits adipogenesis and increases the expression of secreted factors that recruit brown adipose tissue, thereby achieving energy balance by targeting pre-adipocytes, doubling the inhibition of adipogenesis and enhancing brown adipose tissue recruitment compared to mature adipocytes.

Implementation Method 1

a cyclic AMP inducer such as isobutylmethylxanthine or forskolin

Methodology Applied
Scientific EffectAdenylyl cyclase activation:

Implementation Method 2

enhance the expression of secreted factors that selectively recruit brown adipose tissue (BAT) like bone morphogenetic protein-7 (BMP-7), bone morphogenetic protein-4 (BMP-4), vascular endothelial growth factor (VEGF-A) and mitochondrial uncoupling protein (UCP1)

Methodology Applied
Scientific EffectGene expression regulation:

Implementation Method 3

mitochondrial uncoupling protein (UCP1) wherein said enhanced expression of secreted factors that selectively recruit brown adipose tissue (BAT)

Methodology Applied
Scientific EffectMitochondrial uncoupling:

Data Source

PatentEP3194575B1Process and compositions for achieving mammalian energy balance
Publication Date: 2020.04.29 SAMI LABS LTD
  • EP3194575B1 patent drawingFigure 1
  • EP3194575B1 patent drawingFigure 2
  • EP3194575B1 patent drawingFigure 3

AI summary

Disclosed is a method of achieving optimal mammalian energy balance using forskolin on a particular physiological and developmental stage of the mammalian cellular system.